If CMS Finalizes the 6.4% Home Health Payment Cut, Which Operators Face the Steepest Margin Compression?

The Centers for Medicare & Medicaid Services (CMS) proposed a 6.4% aggregate payment reduction for home health agencies in its CY2026 Home Health Prospective Payment System (HH PPS) rule — a cut that, if finalized, would represent one of the largest single-year reductions in the program's history. For publicly traded operators with meaningful home health exposure, the stakes are material. We examine which companies are most vulnerable by mapping their revenue mix, current margins, and balance sheet flexibility.

What's at Stake

The proposed 6.4% cut is driven primarily by CMS's ongoing behavioral adjustment clawback, which seeks to recoup what the agency considers overpayments stemming from the Patient-Driven Groupings Model (PDGM) transition in 2020. Industry groups including the National Association for Home Care & Hospice (NAHC) have pushed back aggressively, arguing the cuts are based on flawed methodology and will force agency closures in rural and underserved markets.

The final rule is expected in late 2026, with an effective date of January 1, 2027. Until then, the proposed cut creates a cloud of uncertainty over every operator with Medicare home health revenue.

Operator-by-Operator Exposure

Aveanna Healthcare (AVAH) — Highest Headline Risk, but Nuanced Exposure

Aveanna is the most commonly cited name in home health reimbursement discussions, but its actual Medicare home health exposure is narrower than it appears. The company's Home Health & Hospice segment generated roughly $56.7 million in quarterly revenue in Q1 2025 — approximately 10% of total revenue ($559 million that quarter). The dominant Private Duty Services segment (82% of revenue) is primarily Medicaid-reimbursed and would not be directly affected by the CMS home health rule.

That said, Aveanna is already operating under considerable financial strain:

With debt-to-EBITDA at 5.1x and barely positive free cash flow, Aveanna has minimal cushion. A 6.4% cut to its ~$225M annual home health revenue would translate to roughly $14-15 million in lost revenue — modest in absolute terms but significant relative to its $26 million in annual free cash flow. Management flagged the proposed rule as a key risk in both Q2 and Q3 2025 earnings calls, noting "uncertainty around the proposed Medicare home health rule for 2026 and its potential cuts to home health benefits."

Verdict: Moderate direct exposure, but the thinnest financial cushion to absorb any cut.

The Ensign Group (ENSG) — Limited Direct Exposure, Strong Offset Capacity

Ensign is primarily a skilled nursing facility (SNF) operator, not a home health company. Its revenue is overwhelmingly driven by post-acute skilled nursing services, with Medicare and Medicaid SNF reimbursement as the core revenue stream. Home health represents a small ancillary offering within its broader portfolio.

Ensign's FY2025 revenue grew 18.7% year-over-year to $5.06 billion, with net income of $344 million and robust free cash flow of $371 million. The company raised guidance three times in 2025 and issued FY2026 EPS guidance of $7.41-$7.61, representing a 14.3% increase at midpoint. Same-store occupancy hit all-time highs of 83.8%.

The CMS home health cut would have negligible direct impact on Ensign's financials. However, there is an indirect read: if home health agencies curtail services or close, SNF operators could see longer patient stays and higher census — a potential tailwind.

Verdict: Minimal direct exposure. Potential indirect beneficiary.

Sotera Health (SHC) — No Home Health Exposure

Sotera Health is a sterilization and lab services company (Sterigenics, Nordion, Nelson Labs) with zero home health revenue. It appears in the related tickers list likely due to its healthcare sector classification, but the CMS home health rule has no bearing on its business model.

Verdict: Not affected by CMS home health cuts.

Amedisys (AMED) — Acquired, No Longer a Public Comparable

Amedisys, formerly the second-largest home health provider in the U.S., was acquired by UnitedHealth Group's Optum division in 2024. As a private subsidiary of UNH, its financials are no longer separately reported. However, the acquisition itself is instructive: UnitedHealth absorbed Amedisys's home health exposure into its massive diversified platform, where a 6.4% Medicare rate cut is far more manageable within a $370B+ revenue base.

Verdict: No longer a standalone public equity. Risk absorbed by UNH.

The Margin Math

Among the publicly traded operators, the vulnerability ranking is clear:

What to Watch

1. Final rule timing: CMS typically publishes the final HH PPS rule in late October/early November. Any reduction from the proposed 6.4% would provide immediate relief.
2. Congressional intervention: Bipartisan bills have been introduced to limit CMS's behavioral adjustment authority. Legislative action could cap or delay cuts.
3. AVAH Q4 2025 earnings: Aveanna's fourth quarter (reporting early 2026) includes a 53rd week that will temporarily inflate results — look through the noise to underlying home health margins.
4. Rural agency closures: If smaller agencies exit, larger operators like Aveanna could gain share even as per-episode reimbursement falls — a volume-vs-rate trade-off worth monitoring.

Bottom Line

Of the operators examined, Aveanna Healthcare faces the steepest margin compression risk — not because its home health exposure is the largest in absolute terms, but because its leveraged balance sheet (5.1x debt/EBITDA) and razor-thin free cash flow ($26M) leave almost no room to absorb a reimbursement cut. Ensign is largely insulated by its SNF-centric model, and Sotera Health has no exposure whatsoever. The final rule — and any potential legislative override — remains the key variable.

Sources: CMS CY2026 HH PPS Proposed Rule; Aveanna Healthcare Q2/Q3 2025 earnings calls; Ensign Group FY2025 annual results; company financial statements via Diggr.